Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate - Concepedia

Concepedia

Publication | Open Access

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

DOI Full Paper Access

580

Citations

18

References

2004

Year

Caio M. Rocha Lima, Mark R. Green, Robert Rotche, Wilson H. Miller, G. Mark Jeffrey, Laura A. Cisar, A. Morganti, Nicoletta Orlando, G. Gruia, Langdon L. Miller

Journal of Clinical Oncology

Abstract

IRINOGEM safely improved the tumor response rate compared with GEM but did not alter overall survival.

References

	Year	Citations

Page 1